PACS

$35.70

Pre-MarketAs of Mar 17, 8:00 PM UTC

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States.

Recent News

Zacks
Mar 17, 2026

Zacks Industry Outlook Highlights BrightSpring Health Services, InnovAge and PACS

BrightSpring Health Services and peers gain from digital health and analytics growth, even as workforce shortages pressure the medical services industry outlook.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

3 Medical Service Industry Stocks Set to Counter Workforce Issues

BTSG, INNV and PACS could benefit as the medical services industry embraces digital health and analytics, though workforce shortages still pressure providers.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 11, 2026

PACS Group, Inc. (PACS) Upgraded to Strong Buy: Here's Why

PACS Group, Inc. (PACS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 10, 2026

Is PACS Group (PACS) Pricing Reflect Its Recent Share Price Pullback And Growth Hopes

If you are looking at PACS Group and wondering whether the current share price lines up with its underlying value, you are not alone. The stock trades at US$34.09 after a 9.8% decline over the last 7 days and an 11.9% decline over the last 30 days, although the 1 year return sits at 170.6%. Recent headlines have focused on PACS Group as a listed operator in the healthcare sector. Investors are watching how it positions itself within the broader US healthcare market. This context has kept...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 5, 2026

PACS vs. MEDP: Which Stock Is the Better Value Option?

PACS vs. MEDP: Which Stock Is the Better Value Option?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.